公开(公告)号：US20230339930A1

公开(公告)日：2023-10-26

申请号：US18004996

申请日：2021-07-07

申请人： Pfizer Inc.

发明人： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Qingyi Yang

IPC分类号： C07D417/14 ,  A61P31/14

CPC分类号： C07D417/14 ,  A61P31/14

摘要： The invention relates to compounds of Formula I




wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

公开(公告)号：US20170096428A1

公开(公告)日：2017-04-06

申请号：US15382778

申请日：2016-12-19

申请人： Pfizer Inc.

发明人： Martin Youngjin Pettersson ,  Christopher William am Ende ,  Douglas Scott Johnson ,  Gregory Wayne Kauffman ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC分类号： C07D471/04

CPC分类号： C07D471/04 ,  A61K31/4985

摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, R10, R11, and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US09193726B2

公开(公告)日：2015-11-24

申请号：US14543020

申请日：2014-11-17

申请人： Pfizer Inc.

发明人： Martin Youngjin Pettersson ,  Douglas Scott Johnson ,  Chakrapani Subramanyam ,  Christopher John O'Donnell ,  Christopher William am Ende ,  Michael Eric Green ,  Nandini Chaturbhai Patel ,  Cory Michael Stiff ,  Tuan Phong Tran ,  Gregory Wayne Kauffman ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC分类号： C07D241/36 ,  C07D471/04

CPC分类号： C07D471/04

摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

摘要翻译： 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

公开(公告)号：US08916564B2

公开(公告)日：2014-12-23

申请号：US14031163

申请日：2013-09-19

申请人： Pfizer Inc.

发明人： Martin Youngjin Pettersson ,  Douglas Scott Johnson ,  Chakrapani Subramanyam ,  Christopher John O'Donnell ,  Christopher William am Ende ,  Michael Eric Green ,  Nandini Chaturbhai Patel ,  Cory Michael Stiff ,  Tuan Phong Tran ,  Gregory Wayne Kauffman ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC分类号： A61K31/4985 ,  C07D471/04

CPC分类号： C07D471/04

摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

摘要翻译： 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

公开(公告)号：US20140088111A1

公开(公告)日：2014-03-27

申请号：US14031163

申请日：2013-09-19

申请人： Pfizer Inc.

发明人： Martin Youngjin Pettersson ,  Douglas Scott Johnson ,  Chakrapani Subramanyam ,  Christopher John O'Donnell ,  Christopher William am Ende ,  Michael Eric Green ,  Nandini Chaturbhai Patel ,  Cory Michael Stiff ,  Tuan Phong Tran ,  Gregory Wayne Kauffman ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

摘要翻译： 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

公开(公告)号：US11541034B2

公开(公告)日：2023-01-03

申请号：US17554091

申请日：2021-12-17

申请人： Pfizer Inc.

发明人： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC分类号： A61K31/401 ,  A61K31/403 ,  C07D403/12 ,  A61K31/427 ,  A61P31/14

摘要： The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20220142976A1

公开(公告)日：2022-05-12

申请号：US17554091

申请日：2021-12-17

申请人： Pfizer Inc.

发明人： Dafydd Rhys Owen ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Liuqing Wei ,  Qingyi Yang ,  Xiaojing Yang

IPC分类号： A61K31/403 ,  A61K31/427 ,  A61P31/14 ,  C07D403/12

摘要： The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US09765073B2

公开(公告)日：2017-09-19

申请号：US15382778

申请日：2016-12-19

申请人： Pfizer Inc.

发明人： Martin Youngjin Pettersson ,  Christopher William am Ende ,  Douglas Scott Johnson ,  Gregory Wayne Kauffman ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC分类号： C07D471/04 ,  A61K31/4985

CPC分类号： C07D471/04 ,  A61K31/4985

摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, R10, R11, and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US09751877B2

公开(公告)日：2017-09-05

申请号：US14877118

申请日：2015-10-07

申请人： Pfizer Inc.

发明人： Martin Youngjin Pettersson ,  Douglas Scott Johnson ,  Chakrapani Subramanyam ,  Christopher John O'Donnell ,  Christopher William am Ende ,  Michael Eric Green ,  Nandini Chaturbhai Patel ,  Cory Michael Stiff ,  Tuan Phong Tran ,  Gregory Wayne Kauffman ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC分类号： A61K31/4985 ,  C07D471/04

CPC分类号： C07D471/04

摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20160024088A1

公开(公告)日：2016-01-28

申请号：US14877118

申请日：2015-10-07

申请人： Pfizer Inc.

发明人： Martin Youngjin Pettersson ,  Douglas Scott Johnson ,  Chakrapani Subramanyam ,  Christopher John O'Donnell ,  Christopher William am Ende ,  Michael Eric Green ,  Nandini Chaturbhai Patel ,  Cory Michael Stiff ,  Tuan Phong Tran ,  Gregory Wayne Kauffman ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

摘要翻译： 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。